One in eight PrEP users in Boston switched from the better-established formulation Truvada to the newer Descovy, but only 7% of those switching had a clinical indication for doing so. Moreover, 14% made potentially harmful switches, as Descovy may have a negative effect on body weight and cholesterol. The data come from Fenway Health, a… Read More »
The first data from the large implementation study of HIV pre-exposure prophylaxis (PrEP) in England, The IMPACT trial, were presented at the joint British HIV Association and British Association of Sexual Health and HIV conference this week. Chief Investigator, Dr Ann Sullivan of London’s Chelsea and Westminster Hospital, told the conference that although there were… Read More »
High initiation and persistence on pre-exposure prophylaxis (PrEP) has been documented in pregnant women in Cape Town, South Africa, with 91% of those offered PrEP starting it and nearly half of those continuing to take PrEP six months later. While women who had given birth and those reporting side effects were less likely to stay… Read More »
This year’s HIV Research for Prevention (HIVR4P) virtual conference featured a large number of sessions examining PrEP usage and discontinuation rates among a variety of users, especially in Africa. Many of the presentations looked at factors that worked as incentives to keep taking PrEP. There is interest in this because, despite higher initiation rates in a… Read More »